UCB S.A. UNSP.ADR 1/2 (F:UNC0) — Market Cap & Net Worth
Market Cap & Net Worth: UCB S.A. UNSP.ADR 1/2 (UNC0)
UCB S.A. UNSP.ADR 1/2 (F:UNC0) has a market capitalization of $44.84 Billion (€38.35 Billion) as of September 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #611 globally and #124 in its home market, demonstrating a -11.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying UCB S.A. UNSP.ADR 1/2's stock price €120.00 by its total outstanding shares 379992422 (379.99 Million). Also see total assets of UCB S.A. UNSP.ADR 1/2 for a full breakdown of the balance sheet.
UCB S.A. UNSP.ADR 1/2 Market Cap History: 2021 to 2026
UCB S.A. UNSP.ADR 1/2's market capitalization history from 2021 to 2026. Data shows growth from $20.88 Billion to $46.65 Billion (25.98% CAGR). Also see UCB S.A. UNSP.ADR 1/2 (UNC0) cash flow conversion for how efficiently the company converts equity into cash flow.
UCB S.A. UNSP.ADR 1/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how UCB S.A. UNSP.ADR 1/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest UCB S.A. UNSP.ADR 1/2 stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
6.71x
UCB S.A. UNSP.ADR 1/2's market cap is 6.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
33.36x
UCB S.A. UNSP.ADR 1/2's market cap is 33.36 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $20.88 Billion | $5.78 Billion | $1.06 Billion | 3.61x | 19.73x |
| 2022 | $15.69 Billion | $5.52 Billion | $418.00 Million | 2.84x | 37.54x |
| 2023 | $16.67 Billion | $5.25 Billion | $343.00 Million | 3.17x | 48.61x |
| 2024 | $41.98 Billion | $6.15 Billion | $1.06 Billion | 6.82x | 39.42x |
| 2025 | $51.98 Billion | $7.74 Billion | $1.56 Billion | 6.71x | 33.36x |
Competitor Companies of UNC0 by Market Capitalization
Companies near UCB S.A. UNSP.ADR 1/2 in the global market cap rankings as of September 16, 2026. Review UCB S.A. UNSP.ADR 1/2 tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to UCB S.A. UNSP.ADR 1/2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
UCB S.A. UNSP.ADR 1/2 Historical Marketcap From 2021 to 2026
Between 2021 and today, UCB S.A. UNSP.ADR 1/2's market cap moved from $20.88 Billion to $ 46.65 Billion, with a yearly change of 25.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €46.65 Billion | -10.26% |
| 2025 | €51.98 Billion | +23.81% |
| 2024 | €41.98 Billion | +151.78% |
| 2023 | €16.67 Billion | +6.26% |
| 2022 | €15.69 Billion | -24.83% |
| 2021 | €20.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of UCB S.A. UNSP.ADR 1/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.84 Billion USD |
| MoneyControl | $44.84 Billion USD |
| MarketWatch | $44.84 Billion USD |
| marketcap.company | $44.84 Billion USD |
| Reuters | $44.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more